Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9417 - 9424 of 12089 results
Latest Medicare Fraud Strike Force Takedown Is The Most Significant To Date
June 19, 2015| Blog| Viewpoint
Regulation A+ goes effective today
June 19, 2015| Blog| Viewpoint
UPDATE: Vivendi Employs Creative Arguments on Damages and the Fraud-on-the-Market Theory to Prevent Class Recovery
June 18, 2015| Blog| Viewpoint
Crowdfunding and IP in Health and Biotech Start-ups (Part 1): The Beginning
June 18, 2015| Blog| Viewpoint
Government Announces Health Care Fraud “Takedown”
June 18, 2015| Blog| Viewpoint
Obama Administration and Private Partners Make a Clean Energy Push
June 17, 2015| Blog| Viewpoint
New Hampshire Establishes Privacy Protections for Student Online Personal Information
June 17, 2015| Blog| Viewpoint
Add Connecticut to Your List of States with a Social Media Privacy Policy Law Favoring Employees
June 16, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|